Alzheimer's disease Archives -

Market Access/ News/ News/ News/ News/ R&D/ Sales and Marketing

Getting approval will only be the first challenge facing lecanemab

Phil Taylor Alzheimer's disease, Biogen, Eisai, lecanemab, neurology, reimbursement 0 Comment

Biogen and Eisai are riding high on the wave of optimism set in motion by the top-line data

Getting approval will only be the first challenge facing lecanemab

https://pharmaphorum.com/news/getting-approval-will-only-be-the-first-challenge-facing-lecanemab/

News/ News/ R&D

Biogen, Eisai say lecanemab has aced phase 3 Alzheimer’s study

Phil Taylor Aduhelm, Alzheimer's disease, Biogen, Eisai, lecanemab, neurology 0 Comment

Biogen and Eisai have resurrected hopes that amyloid-targeting drugs could have a benefit in Alzheimer’s disease with a

Biogen, Eisai say lecanemab has aced phase 3 Alzheimer’s study

https://pharmaphorum.com/news/biogen-eisai-say-lecanemab-has-aced-phase-3-alzheimers-study/

News/ News/ R&D

Merck swings back into Alzheimer’s with $1.1bn Cerevance alliance

Phil Taylor Alzheimer's disease, Cerevance, licensing, Merck & Co, neurology, partnering 0 Comment

Merck & Co’s earlier efforts to find new therapies for Alzheimer’s disease resulted in failure, but the company

Merck swings back into Alzheimer’s with $1.1bn Cerevance alliance

https://pharmaphorum.com/news/merck-swings-back-into-alzheimers-with-1-1bn-cerevance-alliance/

News/ News/ R&D

AC Immune tries to resurrect crenezumab with new data delve

Phil Taylor AC Immune, Alzheimer's disease, crenezumab, Roche 0 Comment

In May, another amyloid targeting drug for Alzheimer’s disease – AC Immune and Roche’s crenezumab – missed the

AC Immune tries to resurrect crenezumab with new data delve

https://pharmaphorum.com/news/ac-immune-tries-to-resurrect-crenezumab-with-new-data-delve/

R&D/ Views & Analysis/ Views and analysis

For neurological disease, solving measurement is the first and biggest hurdle to re-imagining treatment

Jonah Comstock Alzheimer's disease, Biomarkers, digital technology, Parkinson's disease 0 Comment

Neurodegenerative diseases like Parkinson’s and Alzheimer’s affect millions of people worldwide, and their prevalence is only increasing, according

For neurological disease, solving measurement is the first and biggest hurdle to re-imagining treatment

https://pharmaphorum.com/r-d/neurological-disease-solving-measurement-first-hurdle-to-re-imagining-treatment/

News/ News/ R&D

AbbVie cuts Alzheimer’s alliance with Alector in half

Phil Taylor AbbVie, Alector, Alzheimer's disease, immunology, neurology, partnering 0 Comment

AbbVie is pulling out of its collaboration with Alector on the development of Alzheimer’s disease candidate AL003, which

AbbVie cuts Alzheimer’s alliance with Alector in half

https://pharmaphorum.com/news/abbvie-cuts-alzheimers-alliance-with-alector-in-half/

Market Access/ News/ News

Eisai/Biogen could get FDA verdict on new Alzheimer’s drug by 6 Jan

Phil Taylor Aduhelm, Alzheimer's disease, Biogen, Eisai, fda, lecanemab, neurology, regulatory 0 Comment

The FDA has started an accelerated review of Eisai and Biogen’s a new amyloid-targeting antibody lecanemab for Alzheimer’s

Eisai/Biogen could get FDA verdict on new Alzheimer’s drug by 6 Jan

https://pharmaphorum.com/news/eisai-biogen-could-get-fda-verdict-on-new-alzheimers-drug-by-6-jan/

Digital/ News/ News/ R&D

Single MRI-based brain scan could diagnose Alzheimer’s disease, says study

Eloise McLennan Alzheimer's, Alzheimer's disease, Alzheimer's neurology, dementia, MRI imaging, patients, R&D 0 Comment

Alzheimer’s disease could be diagnosed from a single MRI brain scan, according to a new study by Imperial

Single MRI-based brain scan could diagnose Alzheimer’s disease, says study

https://pharmaphorum.com/news/single-mri-based-brain-scan-alzheimers-disease/

Market Access/ News/ News

FDA panel turns down Acadia’s Nuplazid for Alzheimer’s psychosis

Phil Taylor Acadia Pharmaceuticals, Alzheimer's disease, fda, Nuplazid, psychosis 0 Comment

Acadia Pharma’s attempts to extend the indications of its Nuplazid drug in the US to include Alzheimer’s disease-related

FDA panel turns down Acadia’s Nuplazid for Alzheimer’s psychosis

https://pharmaphorum.com/news/fda-panel-turns-down-acadias-nuplazid-for-alzheimers-psychosis/

Trending

Alzheimer’s disease

Login